Introduction
• In the US, approximately one in three adults will experience a major depressive episode within their lifetime, and recent data show that one in twelve experienced a major depressive episode within the past year. Depression results in significant morbidity and mortality; yet, 25% of patients are undiagnosed, and fewer than one-half of those diagnosed receive treatment. For patients who receive treatment, medications are often under-dosed, and followup care often lacks proper symptom assessment, making it difficult to discern whether remission has occurred.
• Unfortunately, disparities exist between evidence-based medicine and clinical practice. The US Preventive Services Task Force (USPSTF) has defined goals for depression screening, a necessary task to ensure accurate diagnosis. Additionally, the American Medical Association (AMA) and Physician Consortium for Performance Improvement (PCPI) have outlined clinical performance measures for the management of patients with major depressive disorder (MDD). Furthermore, the Centers for Medicare and Medicare Services and National Committee for Quality Assurance (NCQA) periodically report on the use of standardized tools for depression screening and antidepressant medication management for the acutephase treatment of MDD as quality measures of care.
• Recognizing the challenges surrounding the care of patients with MDD and the necessity for improved outcomes, the National Committee for Quality Assurance NCQA developed a PI CME initiative in collaboration with an Accreditation Council for Continuing Medical Education (ACCME)-accredited provider (Med-IQ). The initiative focused on the promotion and assessment of national performance measures for clinicians who treat patients with MDD and was approved for Maintenance of Certification by the American Board of Psychiatry and Neurology (ABPN). The results are reported here as an example of potential practice changes that may be achieved and the lessons learned from PI participation. • Participants more than doubled their use of the PHQ-2 (brief form useful in identifying patients in need of intervention) and PHQ-9 (longer form useful for high-risk patients; mirrors DSM-IV criteria) screening questionnaires during initial patient assessments.
Methods

Results
Participation
• 28% more patients were reassessed using standardized criteria in Stage C, which is more sensitive to detecting changes in mental health status than patient-reported impressions.
• 35% more patients receiving antidepressant therapy were assessed for adherence using standardized tools and refill counts.
 Adherence is a challenge as 42% discontinue therapy within first 30 days, 70% within first 90 days
• Significantly more patients were aided in identifying self-management goals.
 Patient management can be aided through collaborative care models that promote ongoing communication and employs multiple strategies.  Collaborative care models also emphasize role of patient self-management. Patients who are supported in achieving their self-care goals have higher ability to alleviate and manage the severity of their depression
Conclusions:
• Participation in a PI activity focused on depression led to improvements in the use of standardized screening and adherence assessment criteria, as well as gains in patient self-management practices
• Improvements in patient care through the use of clinician self-assessment, goal setting, and reassessment suggest clinicians achieved greater awareness and knowledge of evidencebased measures
• Self-assessment practices revealed a gap between self-reported clinician behavior and actual execution in practice
• It is evident that after participation in a PI initiative, these clinicians are better equipped to manage patients and help lessen their burden of disease
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Based on the AMA PI CME model, we designed a PI initiative focused on the screening, treatment and management of patients with MDD: 1. Target audience
• US-based psychiatrists, general and internal medicine physicians, and family practice physicians
Baseline data abstraction (AMA Stage A)
• Retrospective patient chart review assessing execution of predetermined performance measures from a total of 25 patients with diagnosis of MDD
Participant review of baseline data; commitment to improve (AMA Stage B)
• Each participant received a summarized report of their performance of the selected evidence-based standards and their results compared to their peers • Using this data, participants were asked to develop and submit a personal plan for improvement then implement that plan for a minimum period of 3 months
Educational reinforcement
• To support participants' efforts in sustaining their improvement plans, two community of practice audioconferences and a CME-certified online publication were made available
Reassessment (AMA Stage C)
• Participants conducted a second retrospective chart review of 25 patients starting with patients seen after the date of the improvement plan Risk of severe depression 3% 4%
Statistical Analysis
* P value applies to change within the group of data analyzed. 
